All In Biotech

Drug Trial Radar · NCT06415344

Long-term Extension of GTX-102 in Angelman Syndrome

A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients With Angelman Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

66

Actual

Start

Jul 31, 2024

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)

Conditions

  • Angelman Syndrome

Interventions

  • GTX-102Drug

    Antisense Oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 5 Years

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles (UCLA)

    Los Angeles, California

  • University of California, San Diego - Rady Children's Hospital

    San Diego, California

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Weill Cornell Medicine

    New York, New York

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • The Royal Children's Hospital

    Melbourne, Victoria, Australia

  • MAGIC Clinic Ltd

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Childrens Hospital London Health Sciences Centre

    London, Ontario, Canada

  • Childrens Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • The Research Institute of the McGill University Health Centre

    Montreal, Quebec, Canada

  • AP-HM - Hopital de la Timone

    Marseille, France

  • AP-HP Hopital Necker-Enfants Malades

    Paris, France

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, Germany

  • Sheba Medical Center

    Ramat Gan, Israel

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Spain

  • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell

    Sabadell, Spain

  • University of Cambridge

    Cambridge, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.